Dyne Therapeutics Inc (NASDAQ: DYN) is -38.88% lower on its value in year-to-date trading and has touched a low of $6.36 and a high of $47.45 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The DYN stock was last observed hovering at around $14.70 in the last trading session, with the day’s loss setting it -0.3%.
Currently trading at $14.40, the stock is 15.47% and 33.30% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.6 million and changing -2.04% at the moment leaves the stock -33.25% off its SMA200. DYN registered -56.22% loss for a year compared to 6-month loss of -51.09%. The firm has a 50-day simple moving average (SMA 50) of $10.8027 and a 200-day simple moving average (SMA200) of $21.572676.
The stock witnessed a 27.49% gain in the last 1 month and extending the period to 3 months gives it a 25.22%, and is 13.39% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.22% over the week and 3.82% over the month.
Dyne Therapeutics Inc (DYN) has around 191 employees, a market worth around $1.64B and $0.00M in sales. Distance from 52-week low is 126.42% and -69.65% from its 52-week high. The company has generated returns on investments over the last 12 months (-53.42%).
The EPS is expected to shrink by -16.14% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
Dyne Therapeutics Inc (DYN) Top Institutional Holders
281.0 institutions hold shares in Dyne Therapeutics Inc (DYN), with institutional investors hold 111.18% of the company’s shares. The shares outstanding are 113.63M, and float is at 85.23M with Short Float at 27.22%. Institutions hold 110.42% of the Float.
The top institutional shareholder in the company is ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC with over 8.02 million shares valued at $283.03 million. The investor’s holdings represent 8.6697% of the DYN Shares outstanding. As of 2024-06-30, the second largest holder is FCPM III SERVICES B.V. with 7.85 million shares valued at $276.86 million to account for 8.4808 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 7.39 million shares representing 7.9853% and valued at over $260.69 million, while RTW INVESTMENTS, LP holds 6.9044 of the shares totaling 6.39 million with a market value of $225.4 million.
Dyne Therapeutics Inc (DYN) Insider Activity
The most recent transaction is an insider sale by Cox John, the company’s CEO & President. SEC filings show that Cox John sold 4,060 shares of the company’s common stock on Jun 05 ’25 at a price of $13.35 per share for a total of $54201.0. Following the sale, the insider now owns 0.14 million shares.
Dyne Therapeutics Inc disclosed in a document filed with the SEC on Jun 05 ’25 that Kerr Douglas (Chief Medical Officer) sold a total of 1,342 shares of the company’s common stock. The trade occurred on Jun 05 ’25 and was made at $13.35 per share for $17916.0. Following the transaction, the insider now directly holds 92815.0 shares of the DYN stock.
Still, SEC filings show that on Jun 05 ’25, Friedl-Naderer Johanna (Chief Commercial Officer) disposed off 146 shares at an average price of $13.35 for $1949.0. The insider now directly holds 95,911 shares of Dyne Therapeutics Inc (DYN).
